Half-life
~30 minutes to 2 hours
Evidence Level
Preliminary
Mechanism of Action
Mimics lipolytic domain of HGH. Activates beta-3 adrenergic receptors to stimulate lipolysis. Does NOT bind GH receptors or elevate IGF-1 in research studies.
Published Research Ranges & Study Context
Studies have administered: 250–500mcg 2x daily in research literature
Important Research Framing
These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings
Animal studies show 12x more potent fat-burning than HGH per unit. Human trials confirm selective lipolysis without IGF-1 elevation or insulin resistance.
Preliminary
Primarily preclinical + case reports
Side Effects Observed in Research
Generally well-tolerated; less side effect profile than full HGH based on research
Available Configurations (SKU Reference)
FR5
Compounds Studied in Combination
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on HGH Fragment 176-191 — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.